Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency.

Kyei GB, Meng S, Ramani R, Niu A, Lagisetti C, Webb TR, Ratner L.

MBio. 2018 Nov 6;9(6). pii: e01423-18. doi: 10.1128/mBio.01423-18.

2.

Protein-Structure Assisted Optimization of 4,5-Dihydroxypyrimidine-6-Carboxamide Inhibitors of Influenza Virus Endonuclease.

Beylkin D, Kumar G, Zhou W, Park J, Jeevan T, Lagisetti C, Harfoot R, Webby RJ, White SW, Webb TR.

Sci Rep. 2017 Dec 7;7(1):17139. doi: 10.1038/s41598-017-17419-6.

3.

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.

Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, Carcaboso AM, Mann M, Sette A, Garcia KC, Hou Y, Okada H.

J Exp Med. 2018 Jan 2;215(1):141-157. doi: 10.1084/jem.20171046. Epub 2017 Dec 4.

4.

Erratum to "A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore" [Bioorg. Med. Chem. Lett. 27 (2017) 406-412].

Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR.

Bioorg Med Chem Lett. 2017 Mar 15;27(6):1488-1489. doi: 10.1016/j.bmcl.2017.02.009. Epub 2017 Feb 16. No abstract available.

PMID:
28214076
5.

Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.

Shirai CL, White BS, Tripathi M, Tapia R, Ley JN, Ndonwi M, Kim S, Shao J, Carver A, Saez B, Fulton RS, Fronick C, O'Laughlin M, Lagisetti C, Webb TR, Graubert TA, Walter MJ.

Nat Commun. 2017 Jan 9;8:14060. doi: 10.1038/ncomms14060.

6.

A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.

Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR.

Bioorg Med Chem Lett. 2017 Feb 1;27(3):406-412. doi: 10.1016/j.bmcl.2016.12.056. Epub 2016 Dec 24. Erratum in: Bioorg Med Chem Lett. 2017 Mar 15;27(6):1488-1489.

7.

The spliceosome is a therapeutic vulnerability in MYC-driven cancer.

Hsu TY, Simon LM, Neill NJ, Marcotte R, Sayad A, Bland CS, Echeverria GV, Sun T, Kurley SJ, Tyagi S, Karlin KL, Dominguez-Vidaña R, Hartman JD, Renwick A, Scorsone K, Bernardi RJ, Skinner SO, Jain A, Orellana M, Lagisetti C, Golding I, Jung SY, Neilson JR, Zhang XH, Cooper TA, Webb TR, Neel BG, Shaw CA, Westbrook TF.

Nature. 2015 Sep 17;525(7569):384-8. doi: 10.1038/nature14985. Epub 2015 Sep 2.

8.

Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates.

Shi Y, Joyner AS, Shadrick W, Palacios G, Lagisetti C, Potter PM, Sambucetti LC, Stamm S, Webb TR.

Pharmacol Res Perspect. 2015 Aug;3(4):e00158. doi: 10.1002/prp2.158. Epub 2015 Jun 26.

9.

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.

Xargay-Torrent S, López-Guerra M, Rosich L, Montraveta A, Roldán J, Rodríguez V, Villamor N, Aymerich M, Lagisetti C, Webb TR, López-Otín C, Campo E, Colomer D.

Oncotarget. 2015 Sep 8;6(26):22734-49.

10.

Sudemycin E influences alternative splicing and changes chromatin modifications.

Convertini P, Shen M, Potter PM, Palacios G, Lagisetti C, de la Grange P, Horbinski C, Fondufe-Mittendorf YN, Webb TR, Stamm S.

Nucleic Acids Res. 2014 Apr;42(8):4947-61. doi: 10.1093/nar/gku151. Epub 2014 Mar 11.

11.

Pre-mRNA splicing-modulatory pharmacophores: the total synthesis of herboxidiene, a pladienolide-herboxidiene hybrid analog and related derivatives.

Lagisetti C, Yermolina MV, Sharma LK, Palacios G, Prigaro BJ, Webb TR.

ACS Chem Biol. 2014 Mar 21;9(3):643-8. doi: 10.1021/cb400695j. Epub 2013 Dec 30.

12.

Optimization of antitumor modulators of pre-mRNA splicing.

Lagisetti C, Palacios G, Goronga T, Freeman B, Caufield W, Webb TR.

J Med Chem. 2013 Dec 27;56(24):10033-44. doi: 10.1021/jm401370h. Epub 2013 Dec 11.

13.

Dissecting paclitaxel-microtubule association: quantitative assessment of the 2'-OH group.

Sharma S, Lagisetti C, Poliks B, Coates RM, Kingston DG, Bane S.

Biochemistry. 2013 Apr 2;52(13):2328-36. doi: 10.1021/bi400014t. Epub 2013 Mar 19.

14.

Radiosynthesis of antitumor spliceosome modulators.

Goronga T, Boyd VA, Lagisetti C, Jeffries C, Webb TR.

Appl Radiat Isot. 2011 Sep;69(9):1231-4. doi: 10.1016/j.apradiso.2011.04.008. Epub 2011 Apr 16.

15.

Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing.

Fan L, Lagisetti C, Edwards CC, Webb TR, Potter PM.

ACS Chem Biol. 2011 Jun 17;6(6):582-9. doi: 10.1021/cb100356k. Epub 2011 Mar 7.

16.

Synthetic mRNA splicing modulator compounds with in vivo antitumor activity.

Lagisetti C, Pourpak A, Goronga T, Jiang Q, Cui X, Hyle J, Lahti JM, Morris SW, Webb TR.

J Med Chem. 2009 Nov 26;52(22):6979-90. doi: 10.1021/jm901215m.

17.

Antitumor compounds based on a natural product consensus pharmacophore.

Lagisetti C, Pourpak A, Jiang Q, Cui X, Goronga T, Morris SW, Webb TR.

J Med Chem. 2008 Oct 9;51(19):6220-4. doi: 10.1021/jm8006195. Epub 2008 Sep 13.

18.

Specificity of the N-benzoyl transferase responsible for the last step of Taxol biosynthesis.

Long RM, Lagisetti C, Coates RM, Croteau RB.

Arch Biochem Biophys. 2008 Sep 15;477(2):384-9. doi: 10.1016/j.abb.2008.06.021. Epub 2008 Jun 28.

19.

The dioxanone approach to (2S,3R)-2-C-methylerythritol 4-phosphate and 2,4-cyclodiphosphate, and various MEP analogues.

Lagisetti C, Urbansky M, Coates RM.

J Org Chem. 2007 Dec 21;72(26):9886-95. Epub 2007 Nov 17.

PMID:
18020362

Supplemental Content

Loading ...
Support Center